close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

34.98 +0.85 (+2.51%)
Streaming Delayed Price Updated: 10:05 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces $120 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience to Participate in Upcoming Investor Conferences
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces $50 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Alto Neuroscience, Inc. Class Action: Levi &amp; Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi &amp; Korsinsky About Pending Class Action - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.